



Sheet 1 of 1

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P31220X2C2R2SERIAL NO.
10/024,858**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Leonard, et al.FILING DATE
December 18, 2001GROUP
1625 1615**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
JS	6, 168, 805	01/2001	Hein, et al.			
	5, 776, 969	07/1998	James			
	5, 668, 134	09/1997	Limstra, et al.			
JS	5, 811, 436	09/1998	Leonard, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
JS	WO 95/20964	08/1995	WIPO				
	WO 97/18798	05/1997	WIPO				
	WO 91/13612	09/1991	WIPO				
JS	0 714 663	06/1996	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JS	Caley, et al., The Annals of Pharmacology, 1993, Vol. 27, pp. 1212-1222.
	FDA FOIA Materials, June 1993
	Lund, et al., Acta. Pharmacol. Toxicol., 1979, Vol. 44, pp. 289-295.
	Torii, et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 1991, Vol. 344, pp. 564-567.
	Gale, J. of Pediatric Gast. and Nutrition, 1995, Vol. 21, Suppl. 1, pp. S22-S28.
	Bailey, et al., J. of Psychopharm., 1995, Vol. 9, No. 2, pp. 137-141.
	Finely, The Annals of Pharmacotherapy, 1994, Vol. 28, pp. 1359-1369.
JS	J. van Harten, et al., Neuropsychopharmacology, 1994, Vol. 10, No. 35, pp. 104S.

EXAMINER

Sumera H. Sheikh

DATE CONSIDERED

07/15/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\wjd\paroxetine\p31220 paxil cr\supp. 1449 based on c.rugg.doc